在treprostinil配方之间进行转换:证据和策略
Megan Clarke1, Ali Ataya2, Alison M Turkin3
1Novant Health New Hanover Regional Medical Center, Wilmington, NC, USA.
对于肺动脉高血压而言,在特雷普罗斯尼尔配方之间进行过渡是常见的,但缺乏指导. 这份对100多名患者的综述显示,个性化策略的成功率为80%,这突显了对量身定制方法的需求.
科学领域:
- 药理学 药理学是指药理学的学科.
- 肺部医学 肺部医学
- 临床药房 临床药房
背景情况:
- 特雷普罗斯提尼尔是一种前环素类似物,用于治疗肺动脉高血压 (PAH) 和带间歇性肺病 (PH-ILD) 的肺高血压.
- 存在多种特雷普罗斯尼尔配方 (肠道,口服,吸入),需要经常的患者过渡.
- 目前在临床实践中,对于在特雷普罗斯尼尔配方之间进行过渡的标准化指导缺乏.
研究的目的:
- 审查和总结现有关于安全性,疗效的证据,以及在不同特雷普罗斯尼尔配方之间过渡的技术.
- 为临床医生管理特雷布罗斯尼尔治疗过渡提供综合资源.
- 为PAH和PH-ILD患者制定个性化过渡策略提供信息.
主要方法:
- 系统审查关于特雷普罗斯尼尔配方过渡的已发表文献.
- 包括来自各种临床环境的100多名患者的数据.
- 分析报告的过渡战略,重点关注交叉方法.
主要成果:
- 交叉过渡策略是最常用的.
- 大约80%的审查案例被认为是成功的,尽管成功的定义各不相同.
- 不成功的过渡经常与疾病进展或治疗不耐受性有关.
结论:
- 个性化过渡策略至关重要,考虑到患者的临床状态,偏好和配方药理动力学.
- 优化过渡是维持治疗连续性的关键,并改善治疗特雷布罗斯尼尔的患者的治疗结果.
- 需要对标准化成功指标进行进一步的研究,以完善过渡协议.
更多相关视频
08:38Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
Published on: August 28, 2013
07:28Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
Published on: April 6, 2017
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Inhaled Medications
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
